Compare ABAT & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABAT | AKBA |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 366.2M | 375.0M |
| IPO Year | 2013 | 2014 |
| Metric | ABAT | AKBA |
|---|---|---|
| Price | $3.67 | $1.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $6.00 | $4.67 |
| AVG Volume (30 Days) | ★ 5.4M | 5.2M |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 43.14 | ★ 93.94 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $145.40 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.20 | $0.88 |
| 52 Week High | $11.49 | $4.08 |
| Indicator | ABAT | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 60.12 | 38.20 |
| Support Level | $3.56 | $0.88 |
| Resistance Level | $4.43 | $1.56 |
| Average True Range (ATR) | 0.28 | 0.07 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 75.40 | 43.66 |
American Battery Technology Co is an integrated critical battery minerals company that develops technologies for both primary battery minerals manufacturing and lithium-ion battery recycling. It operates battery recycling facilities that process materials from electric vehicle batteries, stationary battery energy storage systems, and consumer electronics. Additionally, the company advances lithium production projects using proprietary technology to produce battery-grade lithium hydroxide. It generates revenue mainly from its recycling operations and is expanding capacity with strategic partnerships and government grants. The company's activities focus on creating a closed-loop battery materials supply chain to support sustainable manufacturing in the United States.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.